It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and ...

Moderna is recognized as a pioneer in messenger ... Shifting sentiment about the need for annual booster vaccination, competition from alternative therapeutics, and the withdrawal of emergency ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Moderna has filed complaints in the US and Germany ... and stake a claim to the potentially lucrative opportunity for booster shots targeting new variants like Omicron as COVID-19 becomes endemic.

On November 19, 2021, the FDA approved a single booster shot of the Moderna COVID-19 vaccine for those aged 18 and older. A second mRNA booster was later authorized for people 12 years and older with ...